GILD Stock Rose 5.68%, Gilead Reports ‘Positive Data’ on Treating COVID-19 with Remdesivir

Coinspeaker
GILD Stock Rose 5.68%, Gilead Reports ‘Positive Data’ on Treating COVID-19 with Remdesivir

Following the positive news on the remdesivir trial, Gilead stock rebounded. Yesterday, GILD closed at $83.14 per share or 5.68% up. After hours, it added another 2.29% to trade at $85.04. The price is also rising today in the-premarket trading.

GILD Stock Rose 5.68%, Gilead Reports ‘Positive Data’ on Treating COVID-19 with Remdesivir

Coinspeaker

11 total views, 1 views today

Author: toutiao